CBU
MDGL icon

CIBC Bancorp USA’s Madrigal Pharmaceuticals MDGL Stock Holding History

CIBC Bancorp USA’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$479K Buy
+916
New +$438K ﹤0.01% 1243
2025
Q3 		$910K Buy
+1,983
New +$740K 0.01% 697

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIBC Bancorp USA's MDGL Position: Q1 2026 in Review

CIBC Bancorp USA opened a new position in Madrigal Pharmaceuticals (MDGL) in Q1 2026: 916 shares worth $479K. The stake represents ﹤0.01% of the portfolio and ranks #1243 among its holdings. This is a return to the name: CIBC Bancorp USA previously reported a position in MDGL as recently as Q3 2025.

CIBC Bancorp USA first reported a position in MDGL in Q3 2025 and has held it in 2 quarters since. The position peaked at $910K in Q3 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • CIBC Bancorp USA held 916 shares of Madrigal Pharmaceuticals worth $479K as of Q1 2026.
  • Madrigal Pharmaceuticals was a new CIBC Bancorp USA position in Q1 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q1 2026, its #1243 holding.
  • CIBC Bancorp USA first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • CIBC Bancorp USA's Madrigal Pharmaceuticals position peaked at $910K in Q3 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on CIBC Bancorp USA's 13F filing for Q1 2026, filed 12 May 2026.